A the present, given the beneficial effects of PLC on angiogenesis, potential limitations for its clinical employment must be considered, in particular in cancer patients, where increased tumor angiogenesis is considered a unfavorable factor [69]. The gene discussed is HSPG2; the disease is cancer.